Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Aman Opneja"'
Autor:
Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nelroy Jones, Tin‐Yun Tang, Nirav Patil, David L. Bajor, Joel N. Saltzman, Amr Mohamed, Eva Selfridge, Ankit Mangla, Jill Barnholtz‐Sloan, Richard T. Lee
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4397-4404 (2021)
Abstract Background This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. Methods Adult patient
Externí odkaz:
https://doaj.org/article/ec0d8868315542849d7c83ead9b2cb93
Publikováno v:
Case Reports in Medicine, Vol 2015 (2015)
Introduction. Cutaneous paraneoplastic syndromes are a heterogeneous group of skin manifestations that occur in relation to many known malignancies. Paraneoplastic occurrence of SCLE has been noted but is not commonly reported. SCLE association with
Externí odkaz:
https://doaj.org/article/f25fc2bb96244f35b7ef2e9335888020
Autor:
Nirav Patil, Ankit Mangla, Asrar Alahmadi, Nelroy Jones, Richard T. Lee, David L. Bajor, Jill S. Barnholtz-Sloan, Eva Selfridge, Amr Mohamed, Gino Cioffi, Aman Opneja, Tin-Yun Tang, Joel N. Saltzman
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4397-4404 (2021)
Cancer Medicine
Cancer Medicine
Background This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. Methods Adult patients diagnos
Publikováno v:
Thrombosis Research. 170:87-96
Despite significant evidence implicating an important role for neutrophils in thrombosis, their impact on the thrombotic process has remained a matter of controversy. Until 2010, platelets, coagulation factors, fibrinogen and monocytes were implicate
Autor:
Hanping Wu, Christopher Sutter, Robert J. Lewandowski, Sidhartha Tavri, Jennifer R. Eads, Indravadan Patel, Aman Opneja
Publikováno v:
Digestive Disease Interventions. :184-194
Colorectal cancer is the third most common malignancy and the second leading cause of cancer death in the United States. Approximately 20 to 25% of patients have clinically detectable colorectal liver metastases (CLM) at the initial diagnosis, and ne
Publikováno v:
Blood. 136:32-33
Introduction: The risk of venous thromboembolism (VTE) is increased in patients with cancer and contributes to significant morbidity, treatment delays and mortality. The Khorana score is the most well-validated VTE risk prediction tool that guides us
Publikováno v:
Thromb Res
Wound healing is a complex process that consists of multiple phases, each of which are indispensable for adequate repair. Timely initiation and resolution of each of these phases namely, hemostasis, inflammation, proliferation and tissue remodeling,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb955100a84e777f347a4f115f1d7116
https://europepmc.org/articles/PMC6556139/
https://europepmc.org/articles/PMC6556139/
Autor:
Nelroy Jones, Gino Cioffi, Jill S. Barnholtz-Sloan, Asrar Alahmadi, Amr Mohamed, Nirav Patil, Aman Opneja, Joel N. Saltzman, Ankit Mangla, Richard T. Lee, David L. Bajor
Publikováno v:
Journal of Clinical Oncology. 38:504-504
504 Background: This study analyzes the pattern of use of SACT in the treatment and survival of AHCC before and after sorafenib was FDA approved in late 2007. Methods: Adult patients diagnosed with HCC and treated with only chemotherapy (CT) from 200
Autor:
Asrar Alahmadi, Ankit Mangla, David L. Bajor, David B. Mansur, Patrick J Getty, Joel N. Saltzman, Prantesh Jain, Aashish D. Bhatt, Gino Cioffi, John B. Ammori, Richard T. Lee, Nirav Patil, Aman Opneja
Publikováno v:
Journal of Clinical Oncology. 38:498-498
498 Background: Primary liver angiosarcoma (LAS) is a rare and aggressive tumor of the liver. In this analysis of the national cancer database (NCDB) we sought the risk of mortality and factors associated with survival amongst patient diagnosed with
Autor:
Joel N. Saltzman, David L. Bajor, Asrar Alahmadi, Richard T. Lee, Gino Cioffi, Aman Opneja, Jill S. Barnholtz-Sloan, Nirav Patil
Publikováno v:
Journal of Clinical Oncology. 37:e15682-e15682
e15682 Background: HCC is a common cause of mortality in the U.S. among men and women (5thand 7th, respectively) with overall five-year survival of ~18%. Sorafenib was the only FDA approved therapy for advanced HCC from 2007 until 2018. This study an